[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Esophageal Achalasia - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: E54BA77F995EEN
DelveInsight

US$ 3,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Esophageal Achalasia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Esophageal Achalasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Esophageal Achalasia Understanding

The DelveInsight Esophageal Achalasia epidemiology report gives a thorough understanding of the Esophageal Achalasia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Esophageal Achalasia in the US, Europe, and Japan. The report covers the detailed information of the Esophageal Achalasia epidemiology scenario in seven major countries (US, EU5, and Japan).

Esophageal Achalasia Epidemiology Perspective by DelveInsight

The Esophageal Achalasia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Esophageal Achalasia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Esophageal Achalasia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Esophageal Achalasia Detailed Epidemiology Segmentation

The Esophageal Achalasia epidemiology covered in the report provides historical as well as forecasted Esophageal Achalasia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Esophageal Achalasia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
  • The Esophageal Achalasia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Esophageal Achalasia Epidemiology Report and Model provide an overview of the global trends of Esophageal Achalasia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Esophageal Achalasia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Esophageal Achalasia
  • The report provides the segmentation of the Esophageal Achalasia epidemiology
Report Highlights
  • 11-year Forecast of Esophageal Achalasia epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Esophageal Achalasia
  • Cases of Esophageal Achalasia by Mutation Types
  • Esophageal Achalasia Cases associated with Clinical Manifestations
KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Esophageal Achalasia?
  • What are the key findings pertaining to the Esophageal Achalasia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients of Esophageal Achalasia across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
  • What is the disease risk, burden and unmet needs of Esophageal Achalasia?
  • What are the currently available treatments of Esophageal Achalasia?
Reasons to buy

The Esophageal Achalasia Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Esophageal Achalasia market
  • Quantify patient populations in the global Esophageal Achalasia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Esophageal Achalasia therapeutics in each of the markets covered
  • Understand the magnitude of Esophageal Achalasia population by its epidemiology
  • The Esophageal Achalasia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF ESOPHAGEAL ACHALASIA

3. ESOPHAGEAL ACHALASIA: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Esophageal Achalasia Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Esophageal Achalasia Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Esophageal Achalasia Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Esophageal Achalasia Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Esophageal Achalasia Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Esophageal Achalasia Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Esophageal Achalasia Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Esophageal Achalasia Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Esophageal Achalasia Treatment and Management
6.2. Esophageal Achalasia Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report


LIST OF TABLES

List of Table:
Table 1: Esophageal Achalasia Epidemiology in 7MM (2019-2032)
Table 2: Esophageal Achalasia Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Esophageal Achalasia Epidemiology in the United States (2019-2032)
Table 4: Esophageal Achalasia Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Esophageal Achalasia Epidemiology in Germany (2019-2032)
Table 6: Esophageal Achalasia Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Esophageal Achalasia Epidemiology in France (2019-2032)
Table 8: Esophageal Achalasia Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Esophageal Achalasia Epidemiology in Italy (2019-2032)
Table 10: Esophageal Achalasia Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Esophageal Achalasia Epidemiology in Spain (2019-2032)
Table 12: Esophageal Achalasia Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Esophageal Achalasia Epidemiology in the United Kingdom (2019-2032)
Table 14: Esophageal Achalasia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Esophageal Achalasia Epidemiology in Japan (2019-2032)
Table 16: Esophageal Achalasia Diagnosed and Treatable Cases in Japan (2019-2032)


LIST OF FIGURES

List of Figures
Figure 1 Esophageal Achalasia Epidemiology in 7MM (2019-2032)
Figure 2 Esophageal Achalasia Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Esophageal Achalasia Epidemiology in the United States (2019-2032)
Figure 4 Esophageal Achalasia Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Esophageal Achalasia Epidemiology in Germany (2019-2032)
Figure 6 Esophageal Achalasia Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Esophageal Achalasia Epidemiology in France (2019-2032)
Figure 8 Esophageal Achalasia Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Esophageal Achalasia Epidemiology in Italy (2019-2032)
Figure 10 Esophageal Achalasia Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Esophageal Achalasia Epidemiology in Spain (2019-2032)
Figure 12 Esophageal Achalasia Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Esophageal Achalasia Epidemiology in the United Kingdom (2019-2032)
Figure 14 Esophageal Achalasia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Esophageal Achalasia Epidemiology in Japan (2019-2032)
Figure 16 Esophageal Achalasia Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report


More Publications